183 related articles for article (PubMed ID: 27888526)
1. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
Yu X; Liu L; Nie X; Li J; Zhang J; Zhao L; Wang X
J Clin Pharm Ther; 2017 Feb; 42(1):18-26. PubMed ID: 27888526
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
3. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
4. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
7. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
9. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
10. Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
L A; Reddy JM; Chebbi PG; Kumar N; Ar AK; M P; B S AK
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3897-3901. PubMed ID: 34967569
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
12. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
13. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
15. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
[TBL] [Abstract][Full Text] [Related]
16. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
17. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
18. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
19. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Patel KS; Lau JE; Zembillas AS; Gallagher EM
J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
